{"doi":"10.1016/j.drudis.2018.03.008","title":"EU decision-making for marketing authorization of advanced therapy medicinal products: a case study","abstract":null,"journal":"Drug Discovery Today","year":2018,"id":26238,"datarank":2.12161051115859,"base_score":3.6109179126442243,"endowment":3.6109179126442243,"self_citation_contribution":0.5416376868966337,"citation_network_contribution":1.5799728242619564,"self_endowment_contribution":0.5416376868966337,"citer_contribution":1.5799728242619564,"corpus_percentile":null,"corpus_rank":null,"citation_count":36,"citer_count":30,"citers_with_citation_signal":22,"citers_with_endowment":22,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":152260,"name":"Delphi G.M. Coppens","orcid":null,"position":1,"is_corresponding":false},{"id":152261,"name":"Jarno Hoekman","orcid":null,"position":2,"is_corresponding":false},{"id":152262,"name":"Marie L. de Bruin","orcid":"0000-0001-9197-7068","position":3,"is_corresponding":false},{"id":152263,"name":"Hubert G.M. Leufkens","orcid":null,"position":4,"is_corresponding":false},{"id":152264,"name":"Henk-Jan Guchelaar","orcid":null,"position":5,"is_corresponding":false},{"id":152265,"name":"Pauline Meij","orcid":null,"position":6,"is_corresponding":false},{"id":152259,"name":"Sofieke de Wilde","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":3.6109179126442243,"endowment":3.6109179126442243,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"29574211","pmcid":null,"openalex_id":"https://openalex.org/W2792777853","authors":[],"funders":[],"total_grants":0,"fwci":2.7585,"citation_percentile":0.90511928,"influential_citations":0,"citation_trend":[{"year":2018,"count":2},{"year":2019,"count":3},{"year":2020,"count":7},{"year":2021,"count":8},{"year":2022,"count":2},{"year":2023,"count":2},{"year":2024,"count":5},{"year":2025,"count":3},{"year":2026,"count":4}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://doi.org/10.1016/j.drudis.2018.03.008","host_type":"journal"},{"url":"https://doi.org/10.1016/j.drudis.2018.03.008","host_type":"HYBRID"},{"url":"https://doi.org/10.1016/j.drudis.2018.03.008","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1359644617305779?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1359644617305779?httpAccept=text/plain","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/29574211","host_type":"repository"},{"url":"http://hdl.handle.net/1887/75485","host_type":"repository"},{"url":"https://dspace.library.uu.nl/handle/1874/369035","host_type":"repository"},{"url":"https://researchprofiles.ku.dk/da/publications/9725091f-c99e-4870-9385-4b882a6702ba","host_type":"repository"},{"url":"https://hdl.handle.net/1887/75485","host_type":"repository"},{"url":"https://dspace.library.uu.nl/handle/1874/365514","host_type":"repository"}],"fields_of_study":["Biomedical Ethics and Regulation","Pharmaceutical studies and practices","Health Systems, Economic Evaluations, Quality of Life","Business","Medicine","Law","Cell- and Tissue-Based Therapy","Decision Making","Drug Approval","European Union","Humans","Marketing of Health Services","Orphan Drug Production","Patient Safety","Policy Making","Product Surveillance, Postmarketing","Quality Control","Risk Assessment","Risk Factors"],"mesh_terms":["Decision Making","European Union","Humans","Marketing of Health Services","Orphan Drug Production","Policy Making","Product Surveillance, Postmarketing","Quality Control","Risk Factors","Drug Approval","Risk Assessment","Patient Safety","Cell- and Tissue-Based Therapy"],"keywords":["Authorization","Marketing authorization","European union","Business","Marketing","Quality (philosophy)","Risk analysis (engineering)","Medicine","Computer security","Computer science","International trade"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-08T12:54:58.229755Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}